Alliance's Oxygent back on track for cardiac surgery:
This article was originally published in Clinica
Following a setback in January, Alliance Pharmaceutical is once again pushing ahead with plans to develop its oxygen-carrying therapeutic, Oxygent, for use during cardiac surgery. The company had suspended enrolment in a phase III trial of the product in heart bypass procedures after observing an unexpected difference in the incidence of adverse events (AEs) between the treated patients and controls (see Clinica No 942, p 19). A preliminary analysis of the safety data has failed to find evidence to link the product directly to imbalance in AEs, says the San Diego, California company.